Lauren A. Byers
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.
Year:
2026
Supplementary Figure 3 shows the relationship of baseline cfDNA levels and maximum and mean VAF to sum of target lesions, ECOG performance status, presence of liver or lung metastases, and treatment duration.
Year:
2025
Supplementary Table 1 shows PIK3CA and PTEN alterations in baseline ctDNA samples, with associated mutation type, amino acid change, allele frequency, OncoKB classification, SIFT/PolyPhen predictions, and affected protein domain.
Year:
2025
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC). Experimental Design: In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations. Results: Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1 . ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker. Conclusions: The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
Year:
2025
Supplementary Figure 2. Heatmap showing Spearman’s correlation matrix for pairwise comparisons of gene expression variables. Spearman’s correlation coefficient (r) values and associated color coding are shown only for correlations that were statistically significant (P
Year:
2025
Purpose: B7 homolog 3 (B7-H3) is a promising target for antibody–drug conjugates, with ifinatamab deruxtecan demonstrating an objective response rate of 54.8% in previously treated extensive-stage small cell lung cancer (SCLC). This analysis aimed to characterize B7-H3 RNA expression with reference to SCLC molecular subtypes (SCLC-A, SCLC-N, SCLC-P, and SCLC-I) and immune-related parameters. Experimental Design: Tumor RNA expression and mutational burden for 1,721 patients with SCLC were derived from a real-world database (Caris Life Sciences). A predominant molecular subtype was assigned based on RNA expression using a gene-ratio classifier. PD-L1 expression was assessed by IHC (antibody 22C3; positive cutoff: tumor proportion score ≥1%). Results: The predominant molecular subtype was SCLC-A in 848 (49.3%), SCLC-N in 202 (11.7%), SCLC-P in 142 (8.3%), SCLC-I in 291 (16.9%), and equivocal in 238 (13.8%) samples. B7-H3 expression was high and consistent among subtypes ( q > 0.05), whereas DLL3 and SEZ6 expression each differed significantly (both q B7-H3 expression quartiles (range, 39.2%–46.5%). Median (95% confidence interval) B7-H3 expression was comparable between patients with and without prior immunotherapy [18.7 (16.5–21.2) and 17.3 (16.4–18.1) transcripts per million, respectively]. B7-H3 was not correlated with a T-cell signature but showed a strong correlation with HAVCR2 / TIM3 , CD86 , PDCD1LG2 / PD-L2 , and M2 macrophages. Conclusions: B7-H3 showed consistent, high expression across SCLC molecular subtypes, whereas DLL3 and SEZ6 expression varied significantly. These data suggest that B7-H3–targeting antibody–drug conjugates may be active across SCLC subtypes, consistent with the high reported response rates.
Year:
2025
Supplementary Figure 4. Expression of B7-H3 in patients with PNET (n = 212), according to classification as low- or high-grade tumors based on MKI67/Ki-67 mRNA expression. Median age was 66 years (range, 19–89+) and 135 patients (63.7%) were female. Expression levels were quantified as log2(TPM +1). Boxplots indicate the median, interquartile range, and range of values, with diamonds representing outliers.
Year:
2025
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC). Experimental Design: In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations. Results: Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker. Conclusions: The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
Year:
2025
Supplementary Table 1. Antibodies used for immunohistochemistry. Supplementary Table 2. Additional Antibodies used for immunohistochemistry at Daiichi Sankyo. Supplementary Table 3. Biomarker and clinical history of PDX models. Supplementary Table 4. Treatment/control ratios of treated PDX models. Supplementary Table 5. Event-free survival (time to tumor doubling) of treated PDX models. Supplementary Table 6. Mutations in actionable genes in the BCXs. Supplementary Table 7. Copy number alterations in actionable genes in the BCXs. Supplementary Table 8. Mutations in DNA damage repair genes in the BCXs. Supplementary Table 9. Copy number alterations in DNA damage repair genes in the BCXs. Supplementary Table 10. Expression of SLFN11 by IHC. Supplementary Table 11. RPPA Results-Responder vs Non-responder PDX Models. Supplementary Table 12. Treatment/control ratios of BCX.011-CL control and TROP2 models. Supplementary Table 13. Event-free survival (time to tumor doubling) of BCX.011-CL control and TROP2 models. Supplementary Table 14. RPPA Results-Signaling changes common to the responder models. Red changes are common to responders and non-responders. Supplementary Table 15. RPPA Results- Signaling changes common to the Non-Responder models. Red changes are common to responders and non-responders. Supplementary Table 16. Treatment/control ratios of Dato-DXd and Olaparib combination experiments. Supplementary Table 17. Event-free survival (time to tumor doubling) of of Dato-DXd and Olaparib combination experiments.
Year:
2025
Purpose: Datopotamab deruxtecan (Dato-DXd) is a humanized anti–trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to a potent topoisomerase I inhibitor payload (DXd). Dato-DXd has already shown antitumor activity in breast cancer; however, the determinants of response, including the importance of TROP2 expression, remain unclear. We tested the activity of Dato-DXd in a panel of breast cancer patient-derived xenografts (BCX) varying in TROP2 expression. Experimental Design: The antitumor activity of Dato-DXd and isotype-control-DXd (IgG-DXd) was assessed against 11 BCXs varying in TROP2 expression, 10 representing tumors postneoadjuvant chemotherapy. Pharmacodynamic effects were assessed at 24 and 72 hours. The effects of TROP2 expression on Dato-DXd activity was assessed in vitro and in vivo using viral overexpression in BCX-derived cell lines. Results: Models differed in their sensitivity to both Dato-DXd and IgG-DXd. Dato-DXd (10 mg/kg) led to objective response in 4 (36%) models and statistically significant prolongation of event-free survival in 8 (73%) models, whereas IgG-DXd (10 mg/kg) led to response in 1 (9%) and prolonged event-free survival in 3 (27%) models. TROP2 RNA and protein were significantly higher in Dato-DXd–sensitive models. In isogenic cell lines derived from Dato-DXd–resistant BCXs, overexpression of TROP2 conferred Dato-DXd antitumor activity in vitro and in vivo . Dato-DXd increased γH2AX and phospho-KAP1 in the two Dato-DXd–sensitive BCXs but not in a Dato-DXd–resistant BCX. In Dato-DXd–sensitive models, antitumor activity was enhanced in combination with a PARP inhibitor, olaparib. Conclusions: Dato-DXd is active in breast cancer models. Dato-DXd has TROP2-dependent and -independent mediators of activity; however, high TROP2 expression enhances Dato-DXd antitumor activity.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (30)
Xiuning Le
The University of Texas MD Anderson Cancer Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
julien Sage
Professor
Stanford University
Ajay Sheshadri
Assistant Professor
The University of Texas MD Anderson Cancer Center
Qi Wang
The University of Texas MD Anderson Cancer Center
Samera Hamad
Assistant Professor
Cooper Medical School of Rowan University
Charles Rudin
Memorial Sloan Kettering Cancer Center
Carminia Maria Della Corte
Università degli Studi della Campania Luigi Vanvitelli
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Bernard E. Weissman
University of North Carolina at Chapel Hill School of Medicine
John V. Heymach
The University of Texas MD Anderson Cancer Center
Chao Cheng
Associate Professor
Baylor College of Medicine
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Michael Frumovitz
Professor
The University of Texas MD Anderson Cancer Center
Ming Poi
-
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Natalie Vokes
The University of Texas MD Anderson Cancer Center
LI SHEN
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Simon Heeke
Assistant Professor
The University of Texas MD Anderson Cancer Center
Taofeek Owonikoko
Professor and Division Chief
University of Pittsburgh
Balazs Dome
Medical University of Vienna
Clemens Aigner
Professor of Thoracic Surgery
Medical University of Vienna
Senthil Damodaran
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Jia Wu
Associate Professor
The University of Texas MD Anderson Cancer Center
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Tao Wang
The University of Texas MD Anderson Cancer Center
Karin Schelch
Medical University of Vienna
Make your next move.
Prepare your application
Review drafts before you send them.